
Nanoform, a pharmaceutical technology services company, offers nanoforming, formulation and analytical services with supercritical carbon dioxide as process solvent.
nanoform.comCrawled Nov 15, 2026
Niklas Sandler, Nanoform’s chief technology officer, discusses demand for nanoformed drug particles.
Niklas Sandler, Nanoform’s chief technology officer, and Jukka discuss AI applications in drug development.
Nanoform’s brochure explains its history and technology.
In the final edition of PMPS in 2021, Barry Derham,…
Christian Jones, Nanoform’s chief commercial officer, discusses innovation with Dr. Sophia Ononye-Onyia.
Christian Jones, Nanoform’s chief commercial officer, discusses the launch of Nanoform’s US subsidiary.
Gonçalo Rebelo de Andrade, Nanoform’s chief business officer, discusses nanotechnology with Chemicals.
Nanoform appoints Dr. David Rowe as Head of Manufacturing in Helsinki, Finland.
Our CCO, Christian Jones, shared his insights with The Medicine…
Nanoform provides nanotechnology and drug particle engineering services for the pharma industry using CESS technology.
Nanoform receives positive feedback from a UK scientific advice meeting regarding its technology. The company reports significantly improved cash flow in Q2 2026. Discussions with contract development and manufacturing organizations (CDMOs) on sterile Good Manufacturing Practice (GMP) for its biologics technology have also begun.
Aug 2026Nanoform small is powerfulNews article
Nanoform Finland receives positive feedback from the UK Medicines and Healthcare products Regulatory Agency (MHRA) during a scientific advice meeting about its drug candidate **Nanoenzalutamide**. The MHRA acknowledges the potential of the nanoformulated prostate cancer treatment in addressing unmet clinical needs.
Aug 2026Nanoform small is powerfulNews article
Nanoform Finland Plc reports record first-quarter revenue, income, and gross margin in 2026. The company also announces its first exclusivity deal centered on its Biologics technology platform. Financial and partnership milestones highlight strong operational performance and commercial traction.
May 2026Nanoform small is powerfulNews article
Nanoform Finland Plc secures its first exclusivity agreement for a subcutaneous delivery system using ultra-high concentration formulations. The deal targets advanced drug delivery solutions in the pharmaceutical sector, leveraging Nanoform’s proprietary technology platform.
May 2026Nanoform small is powerfulNews article